Evaxion A/S (NASDAQ:EVAX) Releases Earnings Results, Misses Expectations By $0.43 EPS

Evaxion A/S (NASDAQ:EVAX) posted its quarterly earnings results on Thursday. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.43), Zacks reports.

Here are the key takeaways from Evaxion A/S’s conference call:

• EVX-01 phase II translational data showed a 86% immunogenicity rate with 86% de novo T cell responses, and the company expects to report 3‑year clinical outcome data in H2 2026.
• Evaxion demonstrated platform scalability to glioblastoma in collaboration with Duke—personalized vaccine designs were feasible for all 24 tumors, with 21/24 designs combining neoantigens and ERV antigens, supporting broader applicability beyond melanoma.
• In collaboration with the Gates Foundation, the company used AI‑Immunology to design a novel polio vaccine concept (hybrid capsid plus de novo T‑cell antigen), illustrating the platform’s ability to reinvent classical vaccines.
• Financial discipline preserved but runway is limited—cash and equivalents were $18.4M at quarter end, projected operational burn is roughly $14M for 2026, giving a runway into H2 2027 and implying potential need for financing absent partnerships.
• Management and business‑development changes include promotion of Birgitte Rønø to CSO/COO and addition of a BD‑focused board member, with multiple unspecified partnering discussions underway for both assets and the platform.

Evaxion A/S Stock Performance

EVAX stock traded up $0.27 during midday trading on Friday, reaching $4.34. 36,792 shares of the company’s stock traded hands, compared to its average volume of 34,738. The company has a 50-day moving average price of $3.88 and a two-hundred day moving average price of $4.56. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.85 and a current ratio of 5.85. Evaxion A/S has a 52 week low of $1.46 and a 52 week high of $12.15. The firm has a market capitalization of $36.20 million, a PE ratio of -2.95 and a beta of 0.26.

Wall Street Analyst Weigh In

A number of research firms recently commented on EVAX. Wall Street Zen cut shares of Evaxion A/S from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Maxim Group began coverage on shares of Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Evaxion A/S in a report on Friday, April 24th. JonesTrading started coverage on shares of Evaxion A/S in a report on Tuesday, March 10th. They set a “buy” rating and a $10.00 target price on the stock. Finally, Lake Street Capital lowered their target price on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Investors Weigh In On Evaxion A/S

A hedge fund recently bought a new stake in Evaxion A/S stock. Northwestern Mutual Wealth Management Co. purchased a new position in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,000 shares of the company’s stock, valued at approximately $38,000. Northwestern Mutual Wealth Management Co. owned 0.10% of Evaxion A/S as of its most recent filing with the Securities and Exchange Commission (SEC). 11.04% of the stock is owned by institutional investors and hedge funds.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.